Li Jiale, Wang Jiachong, Chen Zigui
Department of Neurosurgery, Haikou Affiliated Hospital of Central South University Xiangya School of Medicine, Haikou, 570208, China.
Mol Cancer. 2025 Jan 13;24(1):13. doi: 10.1186/s12943-024-02215-4.
This review highlights recent progress in exosome-based drug delivery for cancer therapy, covering exosome biogenesis, cargo selection mechanisms, and their application across multiple cancer types. As small extracellular vesicles, exosomes exhibit high biocompatibility and low immunogenicity, making them ideal drug delivery vehicles capable of efficiently targeting cancer cells, minimizing off-target damage and side effects. This review aims to explore the potential of exosomes in cancer therapy, with a focus on applications in chemotherapy, gene therapy, and immunomodulation. Additionally, challenges related to exosome production and standardization are analyzed, highlighting the importance of addressing these issues for their clinical application. In conclusion, exosome-based drug delivery systems offer promising potential for future cancer therapies. Further research should aim to enhance production efficiency and facilitate clinical translation, paving the way for innovative cancer treatment strategies.
本综述重点介绍了基于外泌体的癌症治疗药物递送的最新进展,涵盖外泌体生物发生、货物选择机制及其在多种癌症类型中的应用。作为小细胞外囊泡,外泌体具有高生物相容性和低免疫原性,使其成为能够有效靶向癌细胞、将脱靶损伤和副作用降至最低的理想药物递送载体。本综述旨在探索外泌体在癌症治疗中的潜力,重点关注其在化疗、基因治疗和免疫调节中的应用。此外,还分析了与外泌体生产和标准化相关的挑战,强调了解决这些问题对其临床应用的重要性。总之,基于外泌体的药物递送系统为未来癌症治疗提供了有前景的潜力。进一步的研究应旨在提高生产效率并促进临床转化,为创新的癌症治疗策略铺平道路。